Company: INGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029993
Chunk: 80

Company: Inogen Inc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 80
---
olidated Statements of Cash Flows (continued) 

(amounts in thousands) 

    Years Ended December 31,

    2024

    2023

    2022

    Cash flows from financing activities

    Proceeds from stock options exercised

    —

    384

    44

    Proceeds from employee stock purchases

    811

    1,094

    1,691

    Payment of employment taxes related to release of restricted stock

    (546
    )

    (518
    )

    (1,355
    )

    Net cash provided by financing activities

    265

    960

    380

    Effect of exchange rates on cash

    (281
    )

    67

    (481
    )

    Net decrease in cash, cash equivalents and restricted cash

    (8,077
    )

    (61,522
    )

    (48,510
    )

    Cash, cash equivalents and restricted cash, beginning of period

    125,492

    187,014

    235,524

    Cash, cash equivalents and restricted cash, end of period
     
    $
    117,415

    $
    125,492

    $
    187,014

    Supplemental disclosures of cash flow information

    Cash paid (received) during the period for income taxes, net of refunds received
     
    $
    375

    $
    (703
    )
     
    $
    499

    Supplemental disclosure of non-cash transactions

    Accrued value of earnout related to acquisition

    —

    3,178

    —

    Property and equipment in accounts payable and accrued expenses

    197

    204

    428

See accompanying notes to the consolidated financial statements. 

 F-8

Inogen, Inc. 

Notes to the Consolidated Financial Statements 

(amounts in thousands, except share and per share amounts) 

1. Nature of business Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology business that primarily develops, manufactures, and markets innovative respiratory products, such as portable oxygen concentrators (POCs) used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen